Stonebridge Financial Group (Pennsylvania)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$528K Buy
2,100
+104
+5% +$22.4K 0.04% 170
2026
Q1
$434K Buy
1,996
+316
+19% +$70.1K 0.04% 179
2025
Q4
$384K Buy
1,680
+77
+5% +$17.5K 0.03% 191
2025
Q3
$371K Buy
1,603
+10
+0.6% +$2.04K 0.03% 186
2025
Q2
$296K Buy
1,593
+4
+0.3% +$743 0.03% 194
2025
Q1
$333K Buy
1,589
+25
+2% +$4.86K 0.04% 173
2024
Q4
$278K Buy
+1,564
New +$288K 0.03% 199

Other funds holding ABBV

Stonebridge Financial Group (Pennsylvania)'s ABBV Position: Q2 2026 in Review

Stonebridge Financial Group (Pennsylvania) increased its AbbVie (ABBV) stake by 5.2% in Q2 2026, buying an estimated $22.4K and bringing the position to 2,100 shares worth $528K. The position accounts for 0.04% of the portfolio, ranked #170.

Stonebridge Financial Group (Pennsylvania) first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 3,711 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Stonebridge Financial Group (Pennsylvania) held 2,100 shares of AbbVie worth $528K as of Q2 2026.
  • Stonebridge Financial Group (Pennsylvania) bought 104 AbbVie shares in Q2 2026, an estimated $22.4K.
  • AbbVie made up 0.04% of Stonebridge Financial Group (Pennsylvania)'s portfolio in Q2 2026, its #170 holding.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 3,711 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2026, filed 6 Jul 2026.